Mon, Jan 26, 2015, 2:01 AM EST - U.S. Markets open in 7 hrs 29 mins

Recent

% | $
Quotes you view appear here for quick access.

Guided Therapeutics, Inc Message Board

  • gmeabrk gmeabrk Mar 18, 2014 9:43 AM Flag

    When this does make a move, it will be sudden and it will cause personal butt kicking for those who didn't buy this cheap.

    The stock is at an almost all time low. based upon this recent release, Cartwright realizes the need for Luviva in developing Countries.
    This type of thing is right up individuals like Bill Gates and other philanthropists alley. Inexpensive and very accurate..
    Developing countries are more apt to waive certain aspects of Luviva for approval than the FDA because they need this product..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I certainly hope you are correct. The issue right now is why buy the stock? Their is no catalyst in the horizon. Maybe March 26th? Will GTHP even address the FDA during the conference? The market cares about one thing right now. The FDA. Will the FDA approve Luviva? When is the the face to face meeting with the FDA.... The release this AM was nice but moslty BS in my opinion. Tell me about the FDA!

      • 1 Reply to edfiggy
      • ed, when will you realize that FDA is not the most important item on the menu. There is more to be had internationally with Luviva. Hey, it would be great also to have the FDA approve it but it's not the make or break deal for GTHP. Let other countries have a go at it for it will bring more revenue into the mix and after the FDA see's Luviva's success around the world, then it would be the best possible scenario when it's approved here in the US. GLTU

 
GTHP.OB
0.298+0.001(+0.34%)Oct 30 2:14 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.